Ramucirumab Injection，雷莫西尤单抗注射液

Ramucirumab is a human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), inhibits VEGFR-2 activation, thereby inhibiting ligand-induced endothelial cell proliferation and migration, and ultimately inhibiting tumor angiogenesis. [2]
The anti-angiogenic drug ramucirumab is used to treat patients with hepatocellular carcinoma (HCC) who have previously received sorafenib and whose alpha-fetoprotein (AFP) is ≥400 ng/mL. [3]
Ramucirumab is the first treatment approved by the U.S. Food and Drug Administration (FDA) for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma after chemotherapy, and is also the first FDA-approved biomarker-driven therapy for patients with advanced hepatocellular carcinoma (HCC). [4]
In March 2022, Cialis (ramucirumab) combined with paclitaxel was approved by the National Medical Products Administration, becoming the first and only targeted drug approved for the second-line treatment of advanced gastric cancer in my country. [4]